Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
At Hospital/Institution:  Presbyterian - St. Luke's Medical Center
Keywords/Phrases:  leukemia
Results 1-25 of 956 for your search:
Start Over
Gemtuzumab Ozogamicin in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, or Chronic Myelogenous Leukemia
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 months and over
Trial IDs: CCCWFU# 99213, NCI-2013-00965, NCT01869803
Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients with High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 50 and over
Trial IDs: 2468.00, NCI-2011-00150, 2468, 2468.00A, NCT01300572
Fludarabine Phosphate, Clofarabine, and Busulfan with Vorinostat in Treating Patients with Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and under
Trial IDs: 2012-0999, NCI-2014-01982, NCT02083250
Chemotherapy and Donor Lymphocytes in Treating Older Patients with High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 55 and over
Trial IDs: Pro00043247, NCI-2014-00663, NCT02046122
TK008: Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: TK008, NCI-2011-03649, 2009-012973-37, NCT00914628
Reduced Intensity Conditioning and Bone Marrow Transplant in Treating Patients with Hematologic Diseases
Phase: No phase specified
Type: Treatment
Age: Under 75
Trial IDs: 2013OC116, NCI-2014-02315, 1403M49248, MT2013-33C, NCT02145039
Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Hepatic Impairment
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CFZ002, NCI-2013-01934, NCT01949545
A Study of Venetoclax (GDC-0199, ABT-199) in Combination With Bendamustine And MabThera/Rituxan in Participants With Chronic Lymphocytic Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO28440, NCI-2013-01974, 2012-002351-42, NCT01671904
Safety Study in Nivolumab Alone and in Combination With Ipilimumab or Lirilumab in Lymphoma and Multiple Myeloma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA209-039, NCI-2012-02776, NCT01592370
Reduced Intensity Chemotherapy and Radiation Therapy before Donor Stem Cell Transplant in Treating Patients with Hematologic Malignancies
Phase: No phase specified
Type: Treatment
Age: Not specified
Trial IDs: 15D.323, NCI-2015-01506, 2015-054, NCT02566304
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients with Hematologic Disease
Phase: Phase II
Type: Treatment
Age: 6 months to 45 years
Trial IDs: 2010.00, NCI-2010-00190, 2010, FHCRC 2010.00, Protocol 2010, 6095, NCT00719888
A Study of APTO-253 HCl in Patients With Relapsed or Refractory Hematologic Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 253-HEM1-01, NCI-2014-02507, NCT02267863
Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Phase: No phase specified
Type: Biomarker/Laboratory analysis
Age: Children and adults
Trial IDs: ABTR02B1, NCI-2009-00325, CDR0000271322, COG-ABTR02B1, NCT01005277
Selinexor in Treating Younger Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 months to 21 years
Trial IDs: 13-563, NCI-2014-00936, 13-563 / KPT330, NCT02091245
Combination Chemotherapy in Treating Patients with Recurrent Acute Myeloid Leukemia or Recurrent Acute Lymphoblastic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 64
Trial IDs: 2012-1064, NCI-2013-00548, NCT01794702
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 to 69
Trial IDs: 7195, NCI-2012-01084, CA180-392, NCT01620216
Ruxolitinib Phosphate in Treating Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10262, NCI-2014-00633, NCT02092324
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients with Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: IRB14-0709, NCI-2014-02469, NCT02333162
Ex-Vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-versus-Host Disease
Phase: Phase I
Type: Biomarker/Laboratory analysis, Prevention, Treatment
Age: 18 to 70
Trial IDs: 17263, NCI-2014-01426, MCC-17263, NCT01795573
Expanded Umbilical Cord Blood Product HSC835 in Treating Patients with Hematological Malignancies
Phase: Phase I
Type: Treatment
Age: 18 to 55
Trial IDs: HSC835, NCI-2013-02300, 1107M02622, 2010LS086, CHSC835X2201, MT2010-12, NCT01474681
Decitabine and Selinexor in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: OSU-13182, NCI-2014-00559, 2014C0005, NCT02093403
Start Over